NeuroXess, a Shanghai brain-computer interface startup, has raised RMB 700 million (about US$105 million) in a Series B round co-led by SDIC Juli, Shenzhen Capital Group and TRIWISE (Qinzhi Capital), the company said in an Oct. 28 announcement. It plans to use the money to carry its implant from clinical validation toward volume production, paying for registration trials, a factory and next-generation products.
Founder, CEO and chief scientist Tao Hu said in the press release, translated from Chinese, that the round "will accelerate NeuroXess from clinical validation to large-scale application."
Who invested
The company's announcement and the news outlet VCBeat list a long roster beyond the three co-leads: China Fortune-Tech Capital, Huangpu Investment Group, CoStone Capital, IDG Capital, Morning Star Capital, JUNXI Capital, Huafu Securities, Huasai Zhihui, ZWC Partners and Jiangxi Financial Holding. Existing backers Zhongping Capital and Shanda Capital also took part. NeuroXess did not disclose a valuation in the materials reviewed.
TRIWISE, also known as Qinzhi Capital, said in comments translated by VCBeat that it would "draw on our healthcare industry resources to fully support NeuroXess in accelerating multicenter clinical trials and product approval."
Where the money goes
The company outlined four priorities. The first is a multicenter registration trial, along with approval from China's National Medical Products Administration (NMPA), for its "Triple-Full" system, which it describes as fully implantable, fully wireless and fully functional. It also intends to build mass-production capacity at what it calls its "Super Factory," and to develop next-generation products, iterating its language interface while accelerating a visual one. The fourth item is work on combining brain-computer interfaces with artificial intelligence.
Where the product stands
According to a company notice dated July 27, the registration trial began July 7, 2026, at Huashan Hospital, part of Fudan University, with Prof. Mao Ying as principal investigator. That notice cited 15 hospitals in the multicenter study. VCBeat and TechNode later reported "nearly 20," a gap the company has not explained in the materials reviewed.
